Fundraising Fox
ResistanceBio
DefunctYC W19San Francisco, US · Founded 2016 · Delaware corporation · 15 employees · 19 known investors
Find your way into ResistanceBio
Sign up to see every warm intro you have to ResistanceBio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ResistanceBio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ResistanceBio develops treatments to address drug resistance in cancer patients.
Also known as Viosera Therapeutics
Founders & leadership· Y Combinator alumni (W19)
ResistanceBio was founded in 2016 by Nicholas Goldner and Christopher Bulow.
Board
Investors · 19
How we know: Y Combinator's founder network · av.vc · Not right? Tell us
How we know: Fifty Years's portfolio page · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us
How we know: the Y Combinator directory · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: board seat on SEC Form D · funding news · Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$12.8M disclosed across 1 round · 2024
▶$12.8MraisedJan 2024 · 44 investors · PharmaceuticalsRule 506(b)
- NICHOLAS GOLDNERExecutive Officer, Director
- KYLE LAPHAMExecutive Officer, Director
- OMRI AMIRAV-DRORYDirector
- CHRISTOPHER BULOWExecutive Officer, Director
- Offering amount
- $12.8M
- Amount sold
- $12.8M
- Minimum investment
- $1
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through ResistanceBio went on to found or lead other companies.
Related companies · 5
Companies working in the same space as ResistanceBio.
Legal entities · 1
corporate structureFrequently asked questions
- What does ResistanceBio do?
- ResistanceBio develops treatments to address drug resistance in cancer patients.
- Who founded ResistanceBio?
- ResistanceBio was founded by Nicholas Goldner, Christopher Bulow in 2016.
- Who are ResistanceBio's investors?
- ResistanceBio's investors include Alumni Ventures, Fifty Years, Y Combinator, Archangels, Asymmetry Ventures, Brightstone Venture Capital, Cantos Ventures, Centennial Investors and 11 more.
- How much funding has ResistanceBio raised?
- ResistanceBio has disclosed $12.8M raised across 1 round.
- Where is ResistanceBio headquartered?
- ResistanceBio is headquartered in San Francisco, US.